OKYO Pharma (Nasdaq: OKYO) will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026 at 12:30 PM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will present virtually. OKYO is developing urcosimod for neuropathic corneal pain and plans a global Phase 3 trial.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after ophthalmology conference presentation: OKYO +5.11% in the Jul 21 session
+5.11%
6 alerts
+5.11%Session close to close
+9.0%Peak in 24 hr 54 min
$75.05MMarket Cap
0.9xRel. Volume
In the Jul 21 session, OKYO gained 5.11%, reflecting a notable positive market reaction.
Argus tracked a peak move of +9.0% during that session.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +5.1% in the session following this news. +8.7% followed OKYO's July 7 conference an...
Analysis
The stock moved +5.1% in the session following this news. +8.7% followed OKYO's July 7 conference announcement, while this notice adds another scheduled investor event. The active F-3 shelf and low short positioning remain relevant financing and volatility-risk considerations.
Conference presentations were announced, followed by a negative 24-hour share reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Two recent positive clinical or funding updates were followed by negative 24-hour reactions, while a July 7 conference announcement preceded an 8.7% gain.
"therapies for the treatment of neuropathic corneal pain (NCP)"
Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.
phase 3medical
"initiate a global Phase 3 pivotal clinical trial"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
single-dose regimenmedical
"evaluate a single-dose regimen of urcosimod"
A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.
anterior segment eye diseasesmedical
"treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"
Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.
Details of the event are as follows:
Presenter: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer Date/Time: Wednesday, July 22, 12:30 PM ET Location: Virtual Register to Attend: H.C. Wainwright Registration
About OKYOPharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com
FAQ
When will OKYO Pharma (OKYO) present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference?
OKYO Pharma will present on Wednesday, July 22, 2026 at 12:30 PM ET. According to OKYO Pharma, the company’s CEO and CMO will participate in this virtual ophthalmology conference session, which focuses on its investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
Who will present for OKYO Pharma (OKYO) at the H.C. Wainwright 2026 ophthalmology virtual conference?
The presenters for OKYO Pharma will be CEO Robert J. Dempsey and CMO Flavio Mantelli, MD, PhD. According to OKYO Pharma, they will discuss the company’s clinical-stage ophthalmology programs during the July 22, 2026 virtual conference session.
How can investors register to attend OKYO Pharma’s presentation at the July 22, 2026 H.C. Wainwright ophthalmology conference?
Investors can register through the H.C. Wainwright registration link provided for the virtual conference. According to OKYO Pharma, the event is online-only, and registration is handled directly via H.C. Wainwright’s conference platform for the ophthalmology meeting.
What is OKYO Pharma’s (OKYO) lead program urcosimod for neuropathic corneal pain?
Urcosimod is an investigational therapy being developed for neuropathic corneal pain (NCP). According to OKYO Pharma, the company plans a global Phase 3 pivotal trial using a single-dose regimen of urcosimod to evaluate treatment of NCP in approximately 111 patients.
When does OKYO Pharma plan to start its Phase 3 urcosimod trial for neuropathic corneal pain?
OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year. According to OKYO Pharma, this study will enroll about 111 patients to test a single-dose regimen of urcosimod for neuropathic corneal pain (NCP).
How many patients will be enrolled in OKYO Pharma’s planned Phase 3 trial of urcosimod for NCP?
The planned global Phase 3 trial will enroll approximately 111 patients with neuropathic corneal pain. According to OKYO Pharma, the study is designed to evaluate a single-dose regimen of urcosimod as a potential treatment option in this anterior segment eye disease setting.
